Literature DB >> 26628364

Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface.

Michael Letko1, Thijs Booiman2, Neeltje Kootstra2, Viviana Simon3, Marcel Ooms4.   

Abstract

Human cells express natural antiviral proteins, such as APOBEC3G (A3G), that potently restrict HIV replication. As a counter-defense, HIV encodes the accessory protein Vif, which binds A3G and mediates its proteasomal degradation. Our structural knowledge on how Vif and A3G interact is limited, because a co-structure is not available. We identified specific points of contact between Vif and A3G by using functional assays with full-length A3G, patient-derived Vif variants, and HIV forced evolution. These anchor points were used to model and validate the Vif-A3G interface. The resultant co-structure model shows that the negatively charged β4-α4 A3G loop, which contains primate-specific variation, is the core Vif binding site and forms extensive interactions with a positively charged pocket in HIV Vif. Our data present a functional map of this viral-host interface and open avenues for targeted approaches to block HIV replication by obstructing the Vif-A3G interaction.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26628364      PMCID: PMC4670588          DOI: 10.1016/j.celrep.2015.10.068

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  45 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Authors:  Xianghui Yu; Yunkai Yu; Bindong Liu; Kun Luo; Wei Kong; Panyong Mao; Xiao-Fang Yu
Journal:  Science       Date:  2003-10-16       Impact factor: 47.728

3.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.

Authors:  Shingo Kitamura; Hirotaka Ode; Masaaki Nakashima; Mayumi Imahashi; Yuriko Naganawa; Teppei Kurosawa; Yoshiyuki Yokomaku; Takashi Yamane; Nobuhisa Watanabe; Atsuo Suzuki; Wataru Sugiura; Yasumasa Iwatani
Journal:  Nat Struct Mol Biol       Date:  2012-09-23       Impact factor: 15.369

5.  Origin of the HIV-1 group O epidemic in western lowland gorillas.

Authors:  Mirela D'arc; Ahidjo Ayouba; Amandine Esteban; Gerald H Learn; Vanina Boué; Florian Liegeois; Lucie Etienne; Nikki Tagg; Fabian H Leendertz; Christophe Boesch; Nadège F Madinda; Martha M Robbins; Maryke Gray; Amandine Cournil; Marcel Ooms; Michael Letko; Viviana A Simon; Paul M Sharp; Beatrice H Hahn; Eric Delaporte; Eitel Mpoudi Ngole; Martine Peeters
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

6.  A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Authors:  Gongying Chen; Zhiwen He; Tao Wang; Rongzhen Xu; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

7.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

Authors:  Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad A Khan; Klaus Strebel; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

8.  HIV-1 Vif adaptation to human APOBEC3H haplotypes.

Authors:  Marcel Ooms; Bonnie Brayton; Michael Letko; Susan M Maio; Christopher D Pilcher; Frederick M Hecht; Jason D Barbour; Viviana Simon
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

9.  Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G.

Authors:  Takahide Kouno; Elizabeth M Luengas; Megumi Shigematsu; Shivender M D Shandilya; JingYing Zhang; Luan Chen; Mayuko Hara; Celia A Schiffer; Reuben S Harris; Hiroshi Matsuo
Journal:  Nat Struct Mol Biol       Date:  2015-05-18       Impact factor: 15.369

10.  APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host.

Authors:  Annabel Krupp; Kevin R McCarthy; Marcel Ooms; Michael Letko; Jennifer S Morgan; Viviana Simon; Welkin E Johnson
Journal:  PLoS Pathog       Date:  2013-10-03       Impact factor: 6.823

View more
  32 in total

1.  Smc5/6 Antagonism by HBx Is an Evolutionarily Conserved Function of Hepatitis B Virus Infection in Mammals.

Authors:  Fabien Abdul; Fabien Filleton; Laetitia Gerossier; Alexia Paturel; Janet Hall; Michel Strubin; Lucie Etienne
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

2.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific.

Authors:  Edward L Evans; Jordan T Becker; Stephanie L Fricke; Kishan Patel; Nathan M Sherer
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 4.  Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.

Authors:  Farshad C Azimi; Jeffrey E Lee
Journal:  Protein Sci       Date:  2019-11-29       Impact factor: 6.725

5.  The Structural Interface between HIV-1 Vif and Human APOBEC3H.

Authors:  Marcel Ooms; Michael Letko; Viviana Simon
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

6.  An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

Authors:  Ryan P Bennett; Ryan A Stewart; Priscilla A Hogan; Roger G Ptak; Marie K Mankowski; Tracy L Hartman; Robert W Buckheit; Beth A Snyder; Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Antiviral Res       Date:  2016-11-05       Impact factor: 5.970

Review 7.  APOBEC Enzymes as Targets for Virus and Cancer Therapy.

Authors:  Margaret E Olson; Reuben S Harris; Daniel A Harki
Journal:  Cell Chem Biol       Date:  2017-11-16       Impact factor: 8.116

Review 8.  A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.

Authors:  Ryan P Bennett; Jason D Salter; Harold C Smith
Journal:  Trends Mol Med       Date:  2018-03-30       Impact factor: 11.951

9.  Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.

Authors:  Jiayi Wang; Nadine M Shaban; Allison M Land; William L Brown; Reuben S Harris
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

10.  Structural Basis for a Species-Specific Determinant of an SIV Vif Protein toward Hominid APOBEC3G Antagonism.

Authors:  Jennifer M Binning; Nicholas M Chesarino; Michael Emerman; John D Gross
Journal:  Cell Host Microbe       Date:  2019-12-11       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.